CIK细胞联合TACE治疗原发性肝癌的随机对照研究

CIK cells combined with TACE treatment of primary liver cancer randomized controlled study

目的评价CIK细胞免疫疗法联合TACE治疗肝癌的疗效。方法采用随机数字表将118例确诊HCC分为单纯TACE组及联合CIK组。主要评价治疗后疾病进展时间(TTP)及随访1年、3年总生存率。结果 TACE组TTP平均4.7个月,1、3年生存率分别为51.7%、11.6%。CIK-TACE组TTP平均10.7个月,1、3年生存率分别为86.3%、46%。结论 TACE联合CIK细胞免疫治疗可以更好控制肝脏肿瘤病变,延长生存期。

Objective This study evaluated the effect of CIK cell immunotherapy combined with TACE to treat liver cancer.Methods A random confirmed 118 cases HCC were set into the TACE group and TACE joint CIK group.Major evaluation after treatment is time to disease progression（TTP）,and 1-year follow-up,3-year survival rate.Results TACE group TTP was average of 4.7 months,and 1、3 year survival rate was 51.7% and 11.6%.The CIK-TACE group TTP was average of 10.7 months,and the 1、3 year survival rate was 86.3%,46%.Conclusion TACE combined with CIK cells immunotherapy can better control liver tumor lesions and prolong survival.